NeuCyte, Inc., a Sunnyvale, Calif.-based neuroscience drug discovery company, closed a $6.7m Series A financing.
The round, which brings total funding to date to over $8m, was led by initial investors, Cowin Venture and Leaguer Ventures.
The company intends to use the funds to further develop their SynFire® in vitro CNS drug discovery platform for the identification of novel drug targets for Fragile X Syndrome (FXS) and other genetically defined neurological disorders.
Led by Jonathan Davila, co-founder and CEO, and Tao Huang, co-founder and President, NeuCyte has created a proprietary platform that enables translatable neuroscience, allows for modeling neurological diseases, as well as phenotypic and target-based drug screens in a human context.
Its SynFire neuronal cells are generated from induced pluripotent stem cells (iPSCs) derived from healthy or diseased individuals. The proprietary neuronal reprogramming technology, developed in the laboratories of the Nobel laureate Dr. Thomas Südhof, M.D., Ph.D. and Dr. Marius Wernig, M.D. at Stanford University, can produce large quantities of pure populations of specific neuronal subtypes. The different neuronal subtypes can be mixed and matched, giving researchers flexibility to study a single cell type or co-culture environment consisting of mixed human neuronal subtypes and astroglia.